1 |
Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. : Molecular subgroups of medulloblastoma: an international metaanalysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol 123 : 473-484, 2012
DOI
|
2 |
Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, et al. : Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol 123 : 515-527, 2012
DOI
|
3 |
Kuzan-Fischer CM, Guerreiro Stucklin AS, Taylor MD : Advances in genomics explain medulloblastoma behavior at the bedside. Neurosurgery 64(CN_suppl_1) : 21-26, 2017
DOI
|
4 |
Lafay-Cousin L, Smith A, Chi SN, Wells E, Madden J, Margol A, et al. : Clinical, pathological, and molecular characterization of infant medulloblastomas treated with sequential high-dose chemotherapy. Pediatr Blood Cancer 63 : 1527-1534, 2016
DOI
|
5 |
Lau J, Schmidt C, Markant SL, Taylor MD, Wechsler-Reya RJ, Weiss WA : Matching mice to malignancy: molecular subgroups and models of medulloblastoma. Childs Nerv Syst 28 : 521-532, 2012
DOI
|
6 |
Law N, Smith ML, Greenberg M, Bouffet E, Taylor MD, Laughlin S, et al. : Executive function in paediatric medulloblastoma: the role of cerebrocerebellar connections. J Neuropsychol 11 : 174-200, 2017
DOI
|
7 |
MacDonald TJ, Aguilera D, Castellino RC : The rationale for targeted therapies in medulloblastoma. Neuro Oncol 16 : 9-20, 2014
|
8 |
Marino S : Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 11 : 17-22, 2005
DOI
|
9 |
Milla LA, Arros A, Espinoza N, Remke M, Kool M, Taylor MD, et al. : Neogenin1 is a sonic hedgehog target in medulloblastoma and is necessary for cell cycle progression. Int J Cancer 134 : 21-31, 2014
DOI
|
10 |
Mille F, Tamayo-Orrego L, Levesque M, Remke M, Korshunov A, Cardin J, et al. : The Shh receptor Boc promotes progression of early medulloblastoma to advanced tumors. Dev Cell 31 : 34-47, 2014
DOI
|
11 |
Morrissy AS, Cavalli FMG, Remke M, Ramaswamy V, Shih DJH, Holgado BL, et al. : Spatial heterogeneity in medulloblastoma. Nat Genet 49 : 780-788, 2017
DOI
|
12 |
Morrissy AS, Garzia L, Shih DJ, Zuyderduyn S, Huang X, Skowron P, et al. : Divergent clonal selection dominates medulloblastoma at recurrence. Nature 529 : 351-357, 2016
DOI
|
13 |
Moxon-Emre I, Bouffet E, Taylor MD, Laperriere N, Scantlebury N, Law N, et al. : Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol 32 : 1760-1768, 2014
DOI
|
14 |
Moxon-Emre I, Taylor MD, Bouffet E, Hardy K, Campen CJ, Malkin D, et al. : Intellectual outcome in molecular subgroups of medulloblastoma. J Clin Oncol 34 : 4161-4170, 2016
DOI
|
15 |
Mumert M, Dubuc A, Wu X, Northcott PA, Chin SS, Pedone CA, et al. : Functional genomics identifies drivers of medulloblastoma dissemination. Cancer Res 72 : 4944-4953, 2012
DOI
|
16 |
Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, et al. : The whole-genome landscape of medulloblastoma subtypes. Nature 547 : 311-317, 2017
DOI
|
17 |
Northcott PA, Dubuc AM, Pfister S, Taylor MD : Molecular subgroups of medulloblastoma. Expert Rev Neurother 12 : 871-884, 2012
DOI
|
18 |
Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, et al. : Medulloblastomics: the end of the beginning. Nat Rev Cancer 12 : 818-834, 2012
DOI
|
19 |
Northcott PA, Korshunov A, Pfister SM, Taylor MD : The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 8 : 340-351, 2012
DOI
|
20 |
Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, et al. : Epigenetic targeting of hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med 20 : 732-740, 2014
DOI
|
21 |
Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, et al. : Mutations in SUFU predispose to medulloblastoma. Nat Genet 31 : 306-310, 2002
DOI
|
22 |
Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. : Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123 : 465-472, 2012
DOI
|
23 |
Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, et al. : Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24 : 1924-1931, 2006
DOI
|
24 |
Taylor MD, Zhang X, Liu L, Hui CC, Mainprize TG, Scherer SW, et al. : Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling. Oncogene 23 : 4577-4583, 2004
DOI
|
25 |
Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, et al. : Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41 : 727-734, 2005
DOI
|
26 |
Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, et al. : Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 17 : 484-495, 2016
DOI
|
27 |
Traenka C, Remke M, Korshunov A, Bender S, Hielscher T, Northcott PA, et al. : Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res 70 : 8003-8014, 2010
DOI
|
28 |
Taipale J, Cooper MK, Maiti T, Beachy PA : Patched acts catalytically to suppress the activity of smoothened. Nature 418 : 892-897, 2002
DOI
|
29 |
Faria CC, Agnihotri S, Mack SC, Golbourn BJ, Diaz RJ, Olsen S, et al. : Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. Oncotarget 6 : 21718-21729, 2015
|
30 |
Dubuc AM, Remke M, Korshunov A, Northcott PA, Zhan SH, Mendez-Lago M, et al. : Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol 125 : 373-384, 2013
DOI
|
31 |
Faria CC, Golbourn BJ, Dubuc AM, Remke M, Diaz RJ, Agnihotri S, et al. : Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. Cancer Res 75 : 134-146, 2015
|
32 |
Gajjar A, Pfister SM, Taylor MD, Gilbertson RJ : Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res 20 : 5630-5640, 2014
DOI
|
33 |
Gajjar A, Pizer B : Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors. Pediatr Blood Cancer 54 : 649-651, 2010
DOI
|
34 |
Gajjar AJ, Robinson GW : Medulloblastoma-translating discoveries from the bench to the bedside. Nat Rev Clin Oncol 11 : 714-722, 2014
DOI
|
35 |
Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, et al. : Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 23 : 7621-7631, 2005
DOI
|
36 |
Wang X, Dubuc AM, Ramaswamy V, Mack S, Gendoo DMA, Remke M, et al. : Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathol 129 : 449-457, 2015
DOI
|
37 |
Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, et al. : Subtypes of medulloblastoma have distinct developmental origins. Nature 468 : 1095-1099, 2010
DOI
|
38 |
Grill J, Sainte-Rose C, Jouvet A, Gentet JC, Lejars O, Frappaz D, et al. : Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 6 : 573-580, 2005
DOI
|
39 |
Triscott J, Lee C, Foster C, Manoranjan B, Pambid MR, Berns R, et al. : Personalizing the treatment of pediatric medulloblastoma: polo-like kinase 1 as a molecular target in high-risk children. Cancer Res 73 : 6734-6744, 2013
DOI
|
40 |
Venkataraman S, Alimova I, Balakrishnan I, Harris P, Birks DK, Griesinger A, et al. : Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget 5 : 2355-2371, 2014
|
41 |
Wang X, Ramaswamy V, Remke M, Mack SC, Dubuc AM, Northcott PA, et al. : Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma. Neurosurgery 60 Suppl 1 : 57-63, 2013
DOI
|
42 |
Whittier KL, Boese EA, Gibson-Corley KN, Kirby PA, Darbro BW, Qian Q, et al. : G-protein coupled receptor expression patterns delineate medulloblastoma subgroups. Acta Neuropathol Commun 1 : 66, 2013
DOI
|
43 |
Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, et al. : Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482 : 529-533, 2012
DOI
|
44 |
Yauch RL, Dijkgraaf GJP, Alicke B, Januario T, Ahn CP, Holcomb T, et al. : Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 326 : 572-574, 2009
DOI
|
45 |
Zapotocky M, Mata-Mbemba D, Sumerauer D, Liby P, Lassaletta A, Zamecnik J, et al. : Differential patterns of metastatic dissemination across medulloblastoma subgroups. J Neurosurg Pediatr, 2017 [Epub ahead of print]
|
46 |
Zhou L, Picard D, Ra YS, Li M, Northcott PA, Hu Y, et al. : Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma. Cancer Res 70 : 8199-8210, 2010
DOI
|
47 |
Holgado BL, Guerreiro Stucklin A, Garzia L, Daniels C, Taylor MD : Tailoring medulloblastoma treatment through genomics: making a change, one subgroup at a time. Annu Rev Genomics Hum Genet 18 : 143-166, 2017
DOI
|
48 |
Guerreiro Stucklin AS, Ramaswamy V, Daniels C, Taylor MD : Review of molecular classification and treatment implications of pediatric brain tumors. Curr Opin Pediatr 30 : 3-9, 2018
DOI
|
49 |
Henrich N, Marra CA, Gastonguay L, Mabbott D, Malkin D, Fryer C, et al. : De-escalation of therapy for pediatric medulloblastoma: trade-offs between quality of life and survival. Pediatr Blood Cancer 61 : 1300-1304, 2014
DOI
|
50 |
Hoff von K, Hinkes B, Gerber NU, Deinlein F, Mittler U, Urban C, et al. : Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer 45 : 1209-1217, 2009
DOI
|
51 |
Hovestadt V, Jones DT, Picelli S, Wang W, Kool M, Northcott PA, et al. : Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 510 : 537-541, 2014
DOI
|
52 |
Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. : Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488 : 49-56, 2012
DOI
|
53 |
Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. : Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29 : 1408-1414, 2011
DOI
|
54 |
Northcott PA, Lee C, Zichner T, Stutz AM, Erkek S, Kawauchi D, et al. : Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 511 : 428-434, 2014
DOI
|
55 |
Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, et al. : Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41 : 465-472, 2009
DOI
|
56 |
Kool M, Jones DT, Jager N, Northcott PA, Pugh TJ, Hovestadt V, et al. : Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25 : 393-405, 2014
DOI
|
57 |
Johansson G, Andersson U, Melin B : Recent developments in brain tumor predisposing syndromes. Acta Oncol 55 : 401-411, 2016
DOI
|
58 |
Jones DTW, Jager N, Kool M, Zichner T, Hutter B, Sultan M, et al. : Dissecting the genomic complexity underlying medulloblastoma. Nature 488 : 100-105, 2012
DOI
|
59 |
Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. : Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 23 : 23-34, 2013
DOI
|
60 |
Northcott PA, Shih DJ, Remke M, Cho YJ, Kool M, Hawkins C, et al. : Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 123 : 615-626, 2012
DOI
|
61 |
Pambid MR, Berns R, Adomat HH, Hu K, Triscott J, Maurer N, et al. : Overcoming resistance to Sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma. Pediatr Blood Cancer 61 : 107-115, 2014
DOI
|
62 |
Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al. : The genetic landscape of the childhood cancer medulloblastoma. Science 331 : 435-439, 2011
DOI
|
63 |
Pei Y, Liu KW, Wang J, Garancher A, Tao R, Esparza LA, et al. : HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma. Cancer Cell 29 : 311-323, 2016
DOI
|
64 |
Perreault S, Ramaswamy V, Achrol AS, Chao K, Liu TT, Shih D, et al. : MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 35 : 1263-1269, 2014
DOI
|
65 |
Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. : Novel mutations target distinct subgroups of medulloblastoma. Nature 488 : 43-48, 2012
DOI
|
66 |
Ramaswamy V, Taylor MD : Medulloblastoma: from myth to molecular. J Clin Oncol 35 : 2355-2363, 2017
DOI
|
67 |
Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J, et al. : Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148 : 59-71, 2012
DOI
|
68 |
Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, et al. : Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 29 : 2717-2723, 2011
DOI
|
69 |
Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, et al. : Vismodegib exerts targeted efficacy against recurrent sonic hedgehogsubgroup medulloblastoma: results from phase II Pediatric Brain Tumor Consortium studies PBTC-025B and PBTC-032. J Clin Oncol 33 : 2646- 2654, 2015
DOI
|
70 |
Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. : Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361 : 1173-1178, 2009
DOI
|
71 |
Ramaswamy V, Northcott PA, Taylor MD : FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genet 204 : 577-588, 2011
DOI
|
72 |
Rusert JM, Wu X, Eberhart CG, Taylor MD, Wechsler-Reya RJ : SnapShot: medulloblastoma. Cancer Cell 26 : 940-940.e1, 2014
DOI
|
73 |
Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, et al. : Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352 : 978-986, 2005
DOI
|
74 |
Sabel M, Fleischhack G, Tippelt S, Gustafsson G, Doz F, Kortmann R, et al. : Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol 129 : 515-524, 2016
DOI
|
75 |
Zhukova N, Ramaswamy V, Remke M, Martin DC, Castelo-Branco P, Zhang CH, et al. : WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun 2 : 174, 2014
DOI
|
76 |
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. : Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 31 : 2927-2935, 2013
DOI
|
77 |
Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, et al. : TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28 : 5188-5196, 2010
DOI
|
78 |
Pietsch T, Schmidt R, Remke M, Korshunov A, Hovestadt V, Jones DT, et al. : Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol 128 : 137-149, 2014
DOI
|
79 |
Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, et al. : Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488 : 106-110, 2012
DOI
|
80 |
Ramaswamy V, Nor C, Taylor MD : p53 and Meduloblastoma. Cold Spring Harb Perspect Med 6 : a026278, 2015
|
81 |
Ramaswamy V, Remke M, Adamski J, Bartels U, Tabori U, Wang X, et al. : Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients? Neuro Oncol 18 : 291-297, 2016
DOI
|
82 |
Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, et al. : Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol 131 : 821-831, 2016
DOI
|
83 |
Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, et al. : Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 14 : 1200-1207, 2013
DOI
|
84 |
Ramaswamy V, Remke M, Shih D, Wang X, Northcott PA, Faria CC, et al. : Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. Pediatr Blood Cancer 61 : 1190-1194, 2014
DOI
|
85 |
Shih DJ, Northcott PA, Remke M, Korshunov A, Ramaswamy V, Kool M, et al. : Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 32 : 886-896, 2014
DOI
|
86 |
Schneider C, Ramaswamy V, Kulkarni AV, Rutka JT, Remke M, Tabori U, et al. : Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery. J Neurosurg Pediatr 15 : 236-242, 2015
DOI
|
87 |
Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, et al. : Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol 18 : 958-971, 2017
DOI
|
88 |
Schwalbe EC, Williamson D, Lindsey JC, Hamilton D, Ryan SL, Megahed H, et al. : DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 125 : 359-371, 2013
DOI
|
89 |
Badodi S, Dubuc A, Zhang X, Rosser G, Da Cunha Jaeger M, Kameda- Smith MM, et al. : Convergence of BMI1 and CHD7 on ERK signaling in medulloblastoma. Cell Rep 21 : 2772-2784, 2017
DOI
|
90 |
Alimova I, Venkataraman S, Harris P, Marquez VE, Northcott PA, Dubuc A, et al. : Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer 131 : 1800-1809, 2012
DOI
|
91 |
Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, et al. : BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res 20 : 912-925, 2014
DOI
|
92 |
Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, et al. : Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297 : 1559-1561, 2002
DOI
|
93 |
Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, et al. : Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2 : 51ra70, 2010
|
94 |
Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. : Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31 : 737-754.e6, 2017
DOI
|
95 |
Cohen BH, Geyer JR, Miller DC, Curran JG, Zhou T, Holmes E, et al. : Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 phase I/II study. a report from the Children's Oncology Group. Pediatr Neurol 53 : 31-46, 2015
DOI
|
96 |
Dubuc AM, Northcott PA, Kenney AM, Taylor MD : Calculating a cure for cancer: managing medulloblastoma MATH1-ematically. Expert Rev Neurother 10 : 1489-1492, 2010
DOI
|
97 |
Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, et al. : Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28 : 1345-1350, 2010
DOI
|
98 |
Skowron P, Ramaswamy V, Taylor MD : Genetic and molecular alterations across medulloblastoma subgroups. J Mol Med (Berl) 93 : 1075-1084, 2015
DOI
|
99 |
Suryo Rahmanto A, Savov V, Brunner A, Bolin S, Weishaupt H, Malyukova A, et al. : FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. Embo J 35 : 2192-2212, 2016
DOI
|
100 |
Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, et al. : Pleiotropic role for MYCN in medulloblastoma. Genes Dev 24 : 1059-1072, 2010
DOI
|
101 |
Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, et al. : Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature 406 : 1005-1009, 2000
DOI
|